Regulation of nitric oxide production in hypothyroidism

Publication date: April 2020Source: Biomedicine & Pharmacotherapy, Volume 124Author(s): Zoran M. Gluvic, Milan M. Obradovic, Emina M. Sudar-Milovanovic, Sonja S. Zafirovic, Djordje J. Radak, Magbubah M. Essack, Vladimir B. Bajic, Gojobori Takashi, Esma R. IsenovicAbstractHypothyroidism is a common endocrine disorder that predominantly occurs in females. It is associated with an increased risk of cardiovascular diseases (CVD), but the molecular mechanism is not known. Disturbance in lipid metabolism, the regulation of oxidative stress, and inflammation characterize the progression of subclinical hypothyroidism. The initiation and progression of endothelial dysfunction also exhibit these changes, which is the initial step in developing CVD. Animal and human studies highlight the critical role of nitric oxide (NO) as a reliable biomarker for cardiovascular risk in subclinical and clinical hypothyroidism. In this review, we summarize the recent literature findings associated with NO production by the thyroid hormones in both physiological and pathophysiological conditions. We also discuss the levothyroxine treatment effect on serum NO levels in hypothyroid patients.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research